13 March 2024

Revoke the Suspension of the Pharmaceutical Product Neoclav (Neoclav Powder for oral suspension 228.5mg Neoclav Powder for oral suspension 457mg)

Reference: CIR-2024-00000041

To all Health facilities and healthcare practitioners in Dubai's private health sector

Referring to the above subject, DHA notifies all health facilities regarding the circular issued by the MOHAP for perusal and adherence to what is stated

Revoke the Suspension of the Pharmaceutical Product Neoclav (Neoclav Powder for oral suspension 228.5mg Neoclav Powder for oral suspension 457mg)

 

Thanks in advance for your good co-operation

 

Drug Control Section

Health Regulation Sector

DHA

Supporting Documents:

رفع التعليق عن المنتج الطبي Neoclav-1-1.pdf:

View Document